BRIEF-Merck's phase iii tailor landmark study demonstrates significant benefits of Erbitux in combination with FOLFOX over FOLFOX alone
April 25 (Reuters) - Merck & Co Inc
* Says phase iii tailor landmark study demonstrates significant benefits of erbitux in combination with FOLFOX over FOLFOX alone
* Merck will work with relevant authorities to make Erbitux available for patients in China as a first-line treatment as soon as possible
* Phase iii tailor study met its primary endpoint of significantly increasing survival in patients with ras wild-type metastatic colorectal cancer
* Safety profile of Erbitux in tailor clinical trial was manageable,similar to observed in other trials, with no unexpected safety findings Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.